Published in Proc Natl Acad Sci U S A on December 15, 1991
Secondary lipid accumulation in lysosomal disease. Biochim Biophys Acta (2008) 1.30
Bone marrow transplantation corrects the enzyme defect in neurons of the central nervous system in a lysosomal storage disease. Proc Natl Acad Sci U S A (1994) 1.27
Brain pathology in Niemann Pick disease type A: insights from the acid sphingomyelinase knockout mice. J Neurochem (2011) 0.97
Cerebellar alterations and gait defects as therapeutic outcome measures for enzyme replacement therapy in α-mannosidosis. J Neuropathol Exp Neurol (2011) 0.89
A novel mouse model of a patient mucolipidosis II mutation recapitulates disease pathology. J Biol Chem (2014) 0.81
Lysosphingolipids inhibit protein kinase C: implications for the sphingolipidoses. Science (1987) 2.29
Ganglioside-mediated modulation of cell growth. Specific effects of GM3 on tyrosine phosphorylation of the epidermal growth factor receptor. J Biol Chem (1986) 2.00
Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease. Brain Res (1976) 1.77
GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency. Science (1977) 1.65
Biochemical studies on a case of feline mannosidosis. Biochem J (1980) 1.38
A new procedure for examining Golgi impregnated neurons by light and electron microscopy. J Neurocytol (1977) 1.27
Alterations in neuron morphology in feline mannosidosis. A Golgi study. Acta Neuropathol (1981) 1.17
Fibroblast growth factor and glutamate: opposing roles in the generation and degeneration of hippocampal neuroarchitecture. J Neurosci (1989) 1.15
A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. Cancer Res (1986) 1.09
Initiation and growth of ectopic neurites and meganeurites during postnatal cortical development in ganglioside storage disease. Brain Res Dev Brain Res (1990) 0.90
Distribution of ectopic neurite growth and other geometrical distortions of CNS neurons in feline GM2 gangliosidosis. Brain Res (1990) 0.86
Further studies on ectopic dendrite growth and other geometrical distortions of neurons in feline GM1 gangliosidosis. Neuroscience (1987) 0.85
Possible role of gangliosides in regulating an adenylate cyclase-linked 5-hydroxytryptamine (5-HT1) receptor. J Neurochem (1985) 0.84
Ectopic dendritogenesis occurs on cortical pyramidal neurons in swainsonine-induced feline alpha-mannosidosis. Brain Res (1985) 0.81
Impaired proteolytic processing of lysosomal N-acetyl-beta-hexosaminidase in cultured fibroblasts from patients with infantile generalized N-acetylneuraminic acid storage disease. Biochem Biophys Res Commun (1988) 0.80
Ectopic dendritogenesis and associated synapse formation in swainsonine-induced neuronal storage disease. J Neurosci (1988) 0.80
Critical role for glycosphingolipids in Niemann-Pick disease type C. Curr Biol (2001) 2.22
Selection of tumor antigens as targets for immune attack using immunohistochemistry: I. Focus on gangliosides. Int J Cancer (1997) 2.13
Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations. J Neuropathol Exp Neurol (2001) 2.01
A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome). Glycobiology (1999) 1.67
Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man. Proc Natl Acad Sci U S A (1999) 1.63
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial. Proc Natl Acad Sci U S A (2001) 1.63
Selection of tumor antigens as targets for immune attack using immunohistochemistry: II. Blood group-related antigens. Int J Cancer (1997) 1.62
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin Cancer Res (2000) 1.48
Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine (1999) 1.33
GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines. Cancer Res (1994) 1.32
Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21. Int J Cancer (2000) 1.30
Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl Acad Sci U S A (1987) 1.30
Optimal sample size for a series of pilot trials of new agents. Biometrics (1996) 1.28
Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates. Vaccine (2000) 1.25
Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer. Clin Cancer Res (1999) 1.20
Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin Cancer Res (1998) 1.19
Alterations in neuron morphology in feline mannosidosis. A Golgi study. Acta Neuropathol (1981) 1.17
Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res (1998) 1.16
Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J Cancer Res Clin Oncol (2001) 1.15
Immunization of ovarian cancer patients with a synthetic Lewis(y)-protein conjugate vaccine: a phase 1 trial. Int J Cancer (2000) 1.15
Reactivity of natural and induced human antibodies to MUC1 mucin with MUC1 peptides and n-acetylgalactosamine (GalNAc) peptides. Int J Cancer (2000) 1.15
GABAergic neuroaxonal dystrophy and other cytopathological alterations in feline Niemann-Pick disease type C. Acta Neuropathol (1997) 1.13
Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res (1996) 1.12
Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide. Int J Cancer (2000) 1.10
A murine monoclonal antibody detecting N-acetyl- and N-glycolyl-GM2: characterization of cell surface reactivity. Cancer Res (1986) 1.09
Cell-mediated cytotoxicity for cultured autologous melanoma cells. Int J Cancer (1979) 1.09
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res (1995) 1.09
Lysosomal storage diseases of animals: an essay in comparative pathology. Vet Pathol (1997) 1.08
HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst (1981) 1.08
Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells. Cancer Immunol Immunother (1999) 1.06
Purification of feline lysosomal alpha-mannosidase, determination of its cDNA sequence and identification of a mutation causing alpha-mannosidosis in Persian cats. Biochem J (1997) 1.06
A second generation synthesis of the MBr1 (globo-H) breast tumor antigen: new application of the n-pentenyl glycoside method for achieving complex carbohydrate protein linkages. Chemistry (2000) 1.06
A novel and efficient method for synthetic carbohydrate conjugate vaccine preparation: synthesis of sialyl Tn-KLH conjugate using a 4-(4-N-maleimidomethyl) cyclohexane-1-carboxyl hydrazide (MMCCH) linker arm. Glycoconj J (1998) 1.05
The gangliosidoses: comparative features and research applications. Vet Pathol (1979) 1.05
Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients. Int J Cancer (2001) 1.04
Feline Niemann-Pick disease type C. Am J Pathol (1994) 1.04
Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res (1997) 1.03
Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens. Proc Natl Acad Sci U S A (2000) 1.02
Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res (1995) 0.99
Metabolic abnormalities in feline Niemann-Pick type C heterozygotes. J Inherit Metab Dis (1996) 0.99
Cell-surface antigens of melanoma recognized by human monoclonal antibodies. Proc Natl Acad Sci U S A (1987) 0.98
Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study. Clin Cancer Res (2000) 0.98
Lysosomal dysfunction causes neurodegeneration in mucolipidosis II 'knock-in' mice. Brain (2012) 0.97
Ganglioside expression on human malignant melanoma assessed by quantitative immune thin-layer chromatography. Int J Cancer (1993) 0.96
Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother (1995) 0.95
Ferret pyramidal cell dendritogenesis: changes in morphology and ganglioside expression during cortical development. J Comp Neurol (1999) 0.95
Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines. Cancer Immunol Immunother (1998) 0.95
Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci U S A (1995) 0.95
Characterization of a mouse monoclonal IgG3 antibody to the tumor-associated globo H structure produced by immunization with a synthetic glycoconjugate. Glycoconj J (1998) 0.94
Ganglioside antigens expressed by human cancer cells. Semin Cancer Biol (1991) 0.94
Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells. Int J Cancer (1982) 0.94
Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens. Clin Cancer Res (1998) 0.93
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. Clin Cancer Res (1996) 0.91
GM2 gangliosidosis in a Japanese spaniel. Acta Neuropathol (1985) 0.91
Antibody response to immunization with purified GD3 ganglioside and GD3 derivatives (lactones, amide and gangliosidol) in the mouse. Immunobiology (1990) 0.91
Mitochondrial dysfunction in the neuronal ceroid-lipofuscinoses (Batten disease). Neurochem Int (2002) 0.90
Sphingomyelin lipidosis in a cat. Vet Pathol (1987) 0.90
Characterization of the rat mutant dystonic (dt): a new animal model of dystonia musculorum deformans. J Neurosci (1984) 0.90
Inherited lysosomal storage disease associated with deficiencies of beta-galactosidase and alpha-neuraminidase in sheep. Am J Med Genet (1988) 0.90
Vaccines for melanoma: translating basic immunology into new therapies. Lancet Oncol (2001) 0.88
Hypertension in rats from injection of cadmium. Arch Environ Health (1966) 0.88
Immunization of colorectal cancer patients with modified ovine submaxillary gland mucin and adjuvants induces IgM and IgG antibodies to sialylated Tn. Cancer Res (1992) 0.87
Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod (1987) 0.87
Intracellular recording and HRP-staining of cortical neurons in feline ganglioside storage disease. Brain Res (1980) 0.87
The clinical and pathologic heterogeneity of feline alpha-mannosidosis. J Vet Intern Med (1989) 0.87
Animal models of diabetes and obesity, including the PBB/Ld mouse. Fed Proc (1976) 0.85
Further studies on ectopic dendrite growth and other geometrical distortions of neurons in feline GM1 gangliosidosis. Neuroscience (1987) 0.85
Altered vitamin E status in Niemann-Pick type C disease. J Lipid Res (2011) 0.84
Onset and regression of neuroaxonal lesions in sheep with mannosidosis induced experimentally with swainsonine. Acta Neuropathol (1982) 0.84
Altered patterns of evoked synaptic activity in cortical pyramidal neurons in feline ganglioside storage disease. Brain Res (1985) 0.83
Ultrastructure of neurites and meganeurites of cortical pyramidal neurons in feline gangliosidosis as revealed by the combined Golgi-EM technique. Brain Res (1981) 0.82
Comparison of approaches for augmenting the serologic response to the individually specific methylcholanthrene-induced sarcoma-Meth A: pretreatment with cyclophosphamide is most effective. J Immunol (1983) 0.81
Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells. Cancer (1985) 0.81
Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res (2000) 0.81
Morphological alterations in neocortical and cerebellar GABAergic neurons in a canine model of juvenile Batten disease. Am J Med Genet (1995) 0.81
Growth of ectopic dendrites on cortical pyramidal neurons in neuronal storage diseases correlates with abnormal accumulation of GM2 ganglioside. J Neurochem (1994) 0.81
Genetically appropriate expression of HLA and DR (IA) alloantigens on human melanoma cell lines. Tissue Antigens (1980) 0.81
Human monoclonal antibody with dual GM2/GD2 specificity derived from an immunized melanoma patient. Proc Natl Acad Sci U S A (1990) 0.81
Ectopic dendritogenesis occurs on cortical pyramidal neurons in swainsonine-induced feline alpha-mannosidosis. Brain Res (1985) 0.81
HLA and DR antigen frequencies in melanoma patients: possible relation to disease prognosis. Tissue Antigens (1985) 0.80
Biochemical and serological characteristics of natural 9-O-acetyl GD3 from human melanoma and bovine buttermilk and chemically O-acetylated GD3. Cancer Res (1990) 0.80
Ovine ceroid lipofuscinosis (OCL6): postulated mechanism of neurodegeneration. Mol Genet Metab (1999) 0.80
Approaches to augmenting the immunogenicity of the ganglioside GM2 in mice: purified GM2 is superior to whole cells. J Immunol (1987) 0.79
Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells. Int J Cancer (1983) 0.79
Characterization of a hamster melanoma-associated ganglioside antigen as 7-O-acetylated disialoganglioside GD3. J Lipid Res (1993) 0.79
Elevated GM2 ganglioside is associated with dendritic proliferation in normal developing neocortex. Brain Res Dev Brain Res (1996) 0.78
Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer (1995) 0.78
Ectopic axon hillock-associated neurite growth is maintained in metabolically reversed swainsonine-induced neuronal storage disease. Brain Res (1987) 0.78
Sphingomyelin lipidosis in a cat: Golgi studies. Acta Neuropathol (1984) 0.78
The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines. Cancer (1985) 0.78
The serologic response to Meth A sarcoma vaccines after cyclophosphamide treatment is additionally increased by various adjuvants. J Immunol (1985) 0.78
Pathology of mucopolysaccharidosis IIIA in Huntaway dogs. Vet Pathol (2007) 0.78
Ferric ion-ferrocyanide staining in ganglioside storage disease establishes that meganeurites are of axon hillock origin and distinct from axonal spheroids. Brain Res (1986) 0.78
Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother (1995) 0.78
Vaccines and other adjuvant therapies for melanoma. Hematol Oncol Clin North Am (1998) 0.78
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res (1999) 0.77
Immunization of mice with fucosyl-GM1 conjugated with keyhole limpet hemocyanin results in antibodies against human small-cell lung cancer cells. Cancer Immunol Immunother (1999) 0.77
Decreased catalepsy response to haloperidol in the genetically dystonic (dt) rat. Brain Res (1984) 0.77
Ganglioside conjugate vaccines. Immunotherapy against tumors of neuroectodermal origin. Mol Chem Neuropathol (1994) 0.76
Clinical results using biochemotherapy as a standard of care in advanced melanoma. Melanoma Res (2002) 0.75